Similarly, binding of a monoclonal antibody to the C-terminal portion of the proteins was outcompeted by the C-terminal peptide however, not by the KIR4.183-120 peptide . We made identical observations using a cell-based competitive binding assay. Antibodies against the KIR4.1 protein were outcompeted by KIR4.183-120 but not by the control peptide . Therefore, serum reactivity to KIR4.1 exists in a significant %age of individuals with multiple sclerosis and is directed against determinants of the first extracellular loop of the proteins.King, President and CEO of Alexza. ‘We are happy with their improvement, as the Guatemala acceptance represents Ferrer's 1st non-EU acceptance and submission of ADASUVE.’ Related StoriesAristada extended launch injection approved to treat adults with schizophreniaNew study compares efficiency of clozapine with regular antipsychotics in adults with schizophreniaAntidepressants can boost depression, feeling cycling in rapid-cycling bipolar disorder individuals’Launching ADASUVE in the 1st Latin American country can be an important milestone in our collaboration with Alexza and our commercial arrange for ADASUVE,’ said Antoni Villaro, Chief Operating Officer of Ferrer. ‘We believe ADASUVE has an important new option for clinicians who deal with patients with agitation connected with schizophrenia or bipolar disorder.’ ADASUVE may be the first and just inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.